Maxalt (Rizatriptan Benzoate)

Rizatriptan selectively stimulates serotonin 5‑HT1B and 5‑HT1D receptors in cranial blood vessels and trigeminal nerve fibers. This action causes vasoconstriction of dilated intracranial arteries and blocks the release of inflammatory neuropeptides, interrupting the migraine cascade and reducing pain.

The appropriate dose of Maxalt is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

The safety of rizatriptan in pregnancy and lactation has not been definitively established. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Maxalt.

To request Maxalt, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Maxalt belongs to the triptan class, which is generally more specific for migraine relief than non‑specific analgesics such as NSAIDs. Compared with other triptans, rizatriptan has a rapid onset of action and a relatively short half‑life, making it suitable for patients who need quick symptom control.

Store Maxalt tablets at ambient temperature, below 25 °C, in the original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain product stability throughout its shelf life.

Maxalt is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably at the first sign of a migraine attack. Do not crush, chew, or split the tablet unless directed by a healthcare professional.

Serious risks include coronary vasospasm, myocardial infarction, and serotonin syndrome, especially when used with other serotonergic drugs. Patients should seek immediate medical attention if they experience chest pain, severe hypertension, or signs of an allergic reaction.

Maxalt is contraindicated in patients with uncontrolled cardiovascular disease, a history of stroke or transient ischemic attack, severe hepatic impairment, or those currently taking MAO inhibitors. It should also be avoided in individuals with known hypersensitivity to rizatriptan or any tablet excipients.